Literature DB >> 26806150

In vitro antimicrobial activity of benzoyl peroxide against Propionibacterium acnes assessed by a novel susceptibility testing method.

Kazuaki Okamoto1, Fumiaki Ikeda2, Shoji Kanayama3, Akiko Nakajima2, Tatsumi Matsumoto2, Ritsuko Ishii2, Masatoshi Umehara4, Naomasa Gotoh5, Naoki Hayashi5, Takako Iyoda6, Kaoru Matsuzaki6, Satoru Matsumoto6, Makoto Kawashima7.   

Abstract

Benzoyl peroxide (BPO), a therapeutic agent for acne vulgaris, was assessed for in vitro antimicrobial activity against Propionibacterium acnes using a novel broth microdilution testing that improved BPO solubility. We searched for a suitable culture medium to measure the minimum inhibitory concentration (MIC) of BPO against P. acnes and finally found the Gifu anaerobic medium (GAM) broth supplemented with 0.1(v/v)% glycerol and 2(v/v)% Tween 80, in which BPO dissolved up to 1250 μg/mL and P. acnes grew well. The MICs and minimum bactericidal concentrations (MBCs) of BPO against 44 clinical isolates of P. acnes collected from Japanese patients with acne vulgaris were determined by our testing method using the supplemented GAM broth. The MICs of BPO were 128 or 256 μg/mL against all isolates of P. acnes regardless of susceptibility to nadifloxacin or clindamycin. The MBCs of BPO were also 128 or 256 μg/mL against the same isolates. Moreover, BPO at the MIC showed a rapid bactericidal activity against P. acnes ATCC11827 in time-kill assay. In conclusion, we could develop a novel assay for the MIC and MBC determinations of BPO against P. acnes, which is reliable and reproducible as a broth microdilution testing and the present results suggest that BPO has a potent bactericidal activity against P. acnes.
Copyright © 2016 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acne vulgaris; Bactericidal; Benzoyl peroxide; MBC; MIC; Propionibacterium acnes

Mesh:

Substances:

Year:  2016        PMID: 26806150     DOI: 10.1016/j.jiac.2015.12.010

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  7 in total

1.  Minimum Contact Time of 1.25%, 2.5%, 5%, and 10% Benzoyl Peroxide for a Bactericidal Effect Against Cutibacterium acnes.

Authors:  Punyanun Boonchaya; Salinee Rojhirunsakool; Nanticha Kamanamool; Saranya Khunkhet; Surasak Yooyongsatit; Montree Udompataikul; Malai Taweechotipatr
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-03-10

2.  In vitro Antimicrobial Activity of Acne Drugs Against Skin-Associated Bacteria.

Authors:  Mark A T Blaskovich; Alysha G Elliott; Angela M Kavanagh; Soumya Ramu; Matthew A Cooper
Journal:  Sci Rep       Date:  2019-10-10       Impact factor: 4.379

3.  Highly Sensitive Detection of Benzoyl Peroxide Based on Organoboron Fluorescent Conjugated Polymers.

Authors:  Mingyuan Yin; Caiyun Zhang; Jing Li; Haijie Li; Qiliang Deng; Shuo Wang
Journal:  Polymers (Basel)       Date:  2019-10-11       Impact factor: 4.329

4.  Safety and efficacy of a novel three-step anti-acne regimen formulated specifically for women.

Authors:  Timothy Falla; Katie Rodan; Kathy Fields; Danielle Ong; Cezary Skobowiat
Journal:  Int J Womens Dermatol       Date:  2020-08-06

5.  Broad spectrum in vitro microbicidal activity of benzoyl peroxide against microorganisms related to cutaneous diseases.

Authors:  Kazuaki Okamoto; Shoji Kanayama; Fumiaki Ikeda; Koki Fujikawa; Shiori Fujiwara; Naoki Nozawa; Sachi Mori; Tatsumi Matsumoto; Naoki Hayashi; Masataka Oda
Journal:  J Dermatol       Date:  2020-12-28       Impact factor: 4.005

Review 6.  New developments in acne treatment: role of combination adapalene-benzoylperoxide.

Authors:  Su Youn Kim; Falk R Ochsendorf
Journal:  Ther Clin Risk Manag       Date:  2016-10-03       Impact factor: 2.423

7.  Exploring the Anti-Acne Potential of Impepho [Helichrysum odoratissimum (L.) Sweet] to Combat Cutibacterium acnes Virulence.

Authors:  Marco Nuno De Canha; Slavko Komarnytsky; Lenka Langhansova; Namrita Lall
Journal:  Front Pharmacol       Date:  2020-01-30       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.